Jenny C. Chang, MD

Emily Herrmann Chair in Cancer Research & Director, Cancer Center
Professor of Medicine in Oncology, Academic Institute
Full Member, Research Institute
Houston Methodist
Weill Cornell Medical College

Chang Lab


Dr. Jenny C. Chang is the Director of Houston Methodist Cancer Center and Emily Herrmann Chair in Cancer Research in Houston, Texas. She obtained her medical degree at Cambridge University in England, and then completed fellowship training in medical oncology at the Royal Marsden Hospital/Institute for Cancer Research in the United Kingdom. She was also awarded a research doctorate from the University of London. Her recent work has focused on the intrinsic therapy resistance of cancer stem cells, which has led to several publications and international presentations. Dr. Chang’s clinical research aims to evaluate novel biologic agents in breast cancer patients.

Description of Research

Dr. Chang has worked in the field of tumor-initiating cells for more than ten years. After her discovery that tumor-initiating cells are chemo-resistant, and that targeting the EGFR/HER2 pathway can decrease this subpopulation, Dr. Chang has played a key role in demonstrating some of the limitations and mechanisms of tumor-initiating cells (Creighton et al., 2009; Li et al., 2008). Her work is now focused on the mechanisms that regulate TICs, as well as initiating and planning clinical trials that target this critical tumor initiating subpopulation. She is also interested in characterizing the cross-talk between these different pathways that may lead to mechanisms of resistance, and has identified some of the chief regulatory pathways involved in TIC self-renewal. She is a world-renown clinical investigator, credited as one of the first to describe intrinsic chemo-resistance of tumor-initiating cells.

Areas Of Expertise

Breast cancer Cancer Stem cells High throughput
Education & Training

MD, University of Cambridge
Research Doctorate, University of London

Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy
Anand, K, Patel, T, Niravath, P, Rodriguez, A, Darcourt, J, Belcheva, A, Boone, T, Ensor, J & Chang, J 2021, , Scientific Reports, vol. 11, no. 1, 82.

Enhancing Inflammation Targeting Using Tunable Leukocyte-Based Biomimetic Nanoparticles
Zinger, A, Sushnitha, M, Naoi, T, Baudo, G, De Rosa, E, Chang, J, Tasciotti, E & Taraballi, F 2021, , ACS Nano, vol. 15, no. 4, pp. 6326-6339.

Benchmarks for Academic Oncology Faculty
Anthony, L, Atweh, G, Bhatia, R, Carey, LA, Chang, JC, Edelman, MJ, Kantoff, PW, Markham, MJ, Messersmith, W, Nelson, EL, Oettel, K, ORegan, R, Verschraegen, CF & Vose, JM 2021, , JCO oncology practice, vol. 17, no. 3, pp. e440-e444.

Acetyl-CoA Synthetase 2: A Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma
Li, Z, Liu, H, He, J, Wang, Z, Yin, Z, You, G, Wang, Z, Davis, RE, Lin, P, Bergsagel, PL, Manasanch, EE, Wong, STC, Esnaola, NF, Chang, JC, Orlowski, RZ, Yi, Q & Yang, J 2021, , Cell Metabolism, vol. 33, no. 1, pp. 78-93.e7.

Analysis of the Implementation of Telehealth Visits for Care of Patients With Cancer in Houston During the COVID-19 Pandemic
Darcourt, JG, Aparicio, K, Dorsey, PM, Ensor, JE, Zsigmond, EM, Wong, ST, Ezeana, CF, Puppala, M, Heyne, KE, Geyer, CE, Phillips, RA, Schwartz, RL & Chang, JC 2021, , JCO oncology practice, vol. 17, no. 1, pp. e36-e43.

ANETT: PhAse II trial of NEoadjuvant TAK-228 plus Tamoxifen in patients with hormone receptor-positive breast cancer
Koca, E, Niravath, PA, Ensor, J, Patel, TA, Li, X, Hemati, P, Wong, H, Qian, W, Boone, T, Zhao, J, Ramshesh, PV, Cohen, AL, Murthy, A, Nair, S, Darcourt, JG, Belcheva, A, Kaklamani, VG & Chang, JCN 2021, , Breast Cancer Research and Treatment, vol. 188, no. 2, pp. 433-439.

Measuring Ovarian Escape in Premenopausal Estrogen Receptor-Positive Breast Cancer Patients on Ovarian Suppression Therapy
Burns, E, Koca, E, Xu, J, McLean, E, Lee, R, Patel, T, Chang, J & Niravath, P 2021, , Oncologist, vol. 26, no. 6, pp. e936-e942.

A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations
Reddy, TP, Rosato, RR, Li, X, Moulder, S, Piwnica-Worms, H & Chang, JC 2020, , Breast Cancer Research, vol. 22, no. 1, 121.

Antihistamine drug ebastine inhibits cancer growth by targeting polycomb group protein EZH2
Li, Q, Liu, KY, Liu, Q, Wang, G, Jiang, W, Meng, Q, Yi, Y, Yang, Y, Wang, R, Zhu, S, Li, C, Wu, L, Zhao, D, Yan, L, Zhang, L, Kim, JS, Zu, X, Kozielski, AJ, Qian, W, Chang, JC, Patnaik, A, Chen, K & Cao, Q 2020, , Molecular Cancer Therapeutics, vol. 19, no. 10, pp. 2023-2033.

Combination PI3K and NOS targeted therapy for metaplastic breast cancer
Reddy, T, Rosato, R, Guzman, L, Qian, W, Zhou, J, Piwnica-Worms, H, Moulder, S & Chang, J 2020, , European Journal of Cancer, vol. 138, pp. S49-S50.

MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC
Franklin, DA, Sharick, JT, Ericsson-Gonzalez, PI, Sanchez, V, Dean, PT, Opalenik, SR, Cairo, S, Judde, JG, Lewis, MT, Chang, JC, Sanders, ME, Cook, RS, Skala, MC, Bordeaux, J, Orozco Bender, J, Vaupel, C, Geiss, G, Hinerfeld, D & Balko, JM 2020, , JCI insight, vol. 5, no. 15, e134290.

Emerging treatment strategies for breast cancer brain metastasis: from translational therapeutics to real-world experience
Ren, D, Cheng, H, Wang, X, Vishnoi, M, Teh, BS, Rostomily, R, Chang, JC, Wong, ST & Zhao, H 2020, , Therapeutic Advances in Medical Oncology, vol. 12.

Metastatic triple-negative breast cancer: Established and emerging treatments
Puri, A, Reddy, TP, Patel, TA & Chang, JC 2020, , Breast Journal, vol. 26, no. 9, pp. 1793-1796.

Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015
the Translational Breast Cancer Research Consortium (TBCRC) 2020, , Breast Cancer Research and Treatment, vol. 181, no. 3, pp. 623-633.

Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer (Breast Cancer Research (2020) 22: 4 DOI: 10.1186/s13058-019-1243-8)
Goldstein, LJ, Perez, RP, Yardley, D, Han, LK, Reuben, JM, Gao, H, McCanna, S, Butler, B, Ruffini, PA, Liu, Y, Rosato, RR & Chang, JC 2020, , Breast Cancer Research, vol. 22, no. 1, 52.

Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs
Reddy, TP, Choi, DS, Anselme, AC, Qian, W, Chen, W, Lantto, J, Horak, ID, Kragh, M, Chang, JC & Rosato, RR 2020, , Breast cancer research : BCR, vol. 22, no. 1, pp. 48.

Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer
Yomtoubian, S, Lee, SB, Verma, A, Izzo, F, Markowitz, G, Choi, H, Cerchietti, L, Vahdat, L, Brown, KA, Andreopoulou, E, Elemento, O, Chang, J, Inghirami, G, Gao, D, Ryu, S & Mittal, V 2020, , Cell Reports, vol. 30, no. 3, pp. 755-770.e6.

A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer
Goldstein, LJ, Perez, RP, Yardley, D, Han, LK, Reuben, JM, Gao, H, McCanna, S, Butler, B, Ruffini, PA, Liu, Y, Rosato, RR & Chang, JC 2020, , Breast Cancer Research, vol. 22, no. 1, 4.

A Phase II Study of the Efficacy and Safety of Chloroquine in Combination With Taxanes in the Treatment of Patients With Advanced or Metastatic Anthracycline-refractory Breast Cancer
Anand, K, Niravath, P, Patel, T, Ensor, J, Rodriguez, A, Boone, T, Wong, ST & Chang, JC 2021, , Clinical Breast Cancer, vol. 21, no. 3, pp. 199-204.

The impact of molecular status on survival outcomes for invasive micropapillary carcinoma of the breast
Lewis, GD, Xing, Y, Haque, WM, Patel, T, Schwartz, MR, Chen, AC, Farach, AM, Hatch, SS, Butler, EB, Chang, JC & Teh, BS 2019, , Breast Journal, vol. 25, no. 6, pp. 1171-1176.